Ocrelizumab versus placebo in primary progressive multiple sclerosis

ORATORIO Clinical Investigators

Research output: Contribution to journalArticlepeer-review

670 Scopus citations

Fingerprint

Dive into the research topics of 'Ocrelizumab versus placebo in primary progressive multiple sclerosis'. Together they form a unique fingerprint.

Medicine & Life Sciences